Recombinant Human PAPPA2 protein (rFc Tag)

• Home
• Products
• Fusion Proteins
• AuthentiKine ELISA Kits
• Recombinant Human PAPPA2 protein (rFc Tag) (Eg2812)

Species

Human

Purity

>90 %, SDS-PAGE

Tag

rFc Tag

Activity

not tested

Cat no : Eg2812

---

Validation Data Gallery

• 

  Purity of Recombinant Human PAPPA2 was determined by SDS-PAGE. The protein was resolved in an SDS-PAGE in reducing (R) conditions and stained using Coomassie blue.

---

Product Information

• Purity: >90 %, SDS-PAGE
• Endotoxin: <0.1 EU/μg protein, LAL method
• Activity:

  Not tested

• Expression: HEK293-derived Human PAPPA2 protein Ser234-Cys1396 (Accession# Q9BXP8-1) with a rabbit IgG Fc tag at the C-terminus.
• GeneID: 60676
• Accession: Q9BXP8-1
• PredictedSize: 155.2 kDa
• SDS-PAGE: 140-220 kDa, reducing (R) conditions
• Formulation: Lyophilized from 0.22 μm filtered solution in PBS, pH 7.4. Normally 5% trehalose and 5% mannitol are added as protectants before lyophilization.
• Reconstitution: Briefly centrifuge the tube before opening. Reconstitute at 0.1-0.5 mg/mL in sterile water.
• Storage Conditions:
  It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
  • Until expiry date, -20℃ to -80℃ as lyophilized proteins.
  • 3 months, -20℃ to -80℃ under sterile conditions after reconstitution.
• Shipping: The product is shipped at ambient temperature. Upon receipt, store it immediately at the recommended temperature.

Background

PAPPA2 (pregnancy-associated plasma protein-A2) was discovered as a protease which specifically cleaves IGF-binding protein (IGFBP)-3 and -5. PAPPA2 is very highly expressed in the placenta relative to all other tissues. PAPPA2 mRNA and protein are increased in association with pre-eclampsia. PAPPA2 deficiency results in growth impairment in humans with expected derangements in biochemical parameters including increased levels of total IGF-1, IGFBP-3, ALS, and growth hormone.

References:

1. Sifakis S, et al. (2018). Mol Med Rep. May;17(5):6435-6440.
2. Fujimoto M, et al. (2020). Mol Cell Endocrinol. Dec 1;518:110967. 
3. Andrew M, et al. (2018). J Endocr Soc. May 28;2(7):646-656.